Tirzepatide (Mounjaro for type 2 diabetes, Zepbound for weight management) is an FDA-approved dual GIP/GLP-1 receptor agonist that reduces appetite and slows gastric emptying
That's why it's so important to understand why someone is struggling before considering whether a GLP-1 medication is appropriate
Additional trials in the TRIUMPH program may address retatrutide effects on cardiovascular outcomes, sleep apnea resolution, and kidney function, though these have not yet been formally announced
Inflammation and GLP-1s Chronic low-grade inflammation, also known as "inflammaging," is a common feature of many chronic diseases, including metabolic disorders, autoimmune conditions, and cardiovascular disease
Eat smaller, more frequent meals Spacing meals and snacks evenly through the day can prevent long gaps without food and lower the risk of sudden drops in blood sugar